Physician profile
Reshma John
NPI 1578964763
$2,423.47
in general payments reported to CMS, 2019-2025
15 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $830 · 2020: $426 · 2021: $82.85 · 2022: $248 · 2023: $149 · 2024: $322 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $493.44 | 2019-2025 | Dailies Total1, Precision 1, Precision7 |
| Johnson & Johnson Vision Care, INC. | $428.40 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $252.24 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $215.54 | 2020-2025 | |
| Glaukos Corporation | $156.65 | 2022 | |
| Genzyme Corporation | $121.35 | 2019 | |
| Bausch & Lomb Americas INC. | $119.88 | 2024 | Miebo, Xiidra |
| Novartis Pharmaceuticals Corporation | $118.77 | 2019 | |
| Oyster Point Pharma, INC. | $106.93 | 2024 | Tyrvaya |
| Akebia Therapeutics INC | $96.61 | 2019 | |
| Biotissue Holdings INC. | $94.89 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $91.73 | 2022 | |
| Coopervision INC. | $90.40 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.